הזינוק בוול סטריט, הפסדי השורטיסטים והסיכוי למנוע סרטן: מניית מודרנה לאן

הערכה

A single trading session erased billions from short sellers after Moderna's stock surged 177% on positive cancer vaccine trial results. The move forced hedge funds to liquidate other winning positions to cover losses, creating ripple effects across the market. The question no one is answering yet: does a promising early stage trial genuinely justify adding $30 billion in market value overnight, or is this momentum detached from fundamentals?